The forefront of ovarian cancer therapy: update on PARP inhibitors von Mirza, M.R., Coleman, R.L., González-Martín, A., Moore, K.N., Colombo, N., Ray-Coquard, I., Pignata, S.

Volltext

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer von Dockery, L E, Gunderson, C C, Moore, K N

Volltext

Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer? von Kristeleit, R.S., Moore, K.N.

Volltext

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I von Moore, K.N., Oza, A.M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G.E., Banerjee, S., Murphy, C.G., Tanyi, J.L., Hirte, H., Konner, J.A., Lim, P.C., Prasad-Hayes, M., Monk, B.J., Pautier, P., Wang, J., Berkenblit, A., Vergote, I., Birrer, M.J.

Volltext

Homologous recombination deficiency testing in first-line ovarian cancer von Moore, K.N., du Bois, A.

Volltext

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option von Buechel, M., Herzog, T.J., Westin, S.N., Coleman, R.L., Monk, B.J., Moore, K.N.

Volltext

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer von Bogani, G., Monk, B.J., Powell, M.A., Westin, S.N., Slomovitz, B., Moore, K.N., Eskander, R.N., Raspagliesi, F., Barretina-Ginesta, M.-P., Colombo, N., Mirza, M.R.

Volltext

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cance... von Liu, J.F., Moore, K.N., Birrer, M.J., Berlin, S., Matulonis, U.A., Infante, J.R., Wolpin, B., Poon, K.A., Firestein, R., Xu, J., Kahn, R., Wang, Y., Wood, K., Darbonne, W.C., Lackner, M.R., Kelley, S.K., Lu, X., Choi, Y.J., Maslyar, D., Humke, E.W., Burris, H.A.

Volltext

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO) von Pothuri, B., Blank, S.V., Myers, T.K., Hines, J.F., Randall, L.M., O'Cearbhaill, R.E., Slomovitz, B.M., Eskander, R.N., Alvarez Secord, A., Coleman, R.L., Walker, J.L., Monk, B.J., Moore, K.N., O'Malley, D.M., Copeland, L.J., Herzog, T.J.

Volltext

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors von McGee, J., Bookman, M., Harter, P., Marth, C., McNeish, I., Moore, K.N., Poveda, A., Hilpert, F., Hasegawa, K., Bacon, M., Gatsonis, C., Brand, A., Kridelka, F., Berek, J., Ottevanger, N., Levy, T., Silverberg, S., Kim, B.-G., Hirte, H., Okamoto, A., Stuart, G., Ochiai, K.

Volltext

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomize... von Banerjee, S., Oza, A.M., Birrer, M.J., Hamilton, E.P., Hasan, J., Leary, A., Moore, K.N., Mackowiak-Matejczyk, B., Pikiel, J., Ray-Coquard, I., Trask, P., Lin, K., Schuth, E., Vaze, A., Choi, Y., Marsters, J.C., Maslyar, D.J., Lemahieu, V., Wang, Y., Humke, E.W., Liu, J.F.

Volltext

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium von Jackson, C.G., Moore, K.N., Cantrell, L., Erickson, B.K., Duska, L.R., Richardson, D.L., Landrum, L.M., Holman, L.L., Walker, J.L., Mannel, R.S., Moxley, K.M., Queimado, L., Cohoon, A., Ding, K., Dockery, L.E.

Volltext

PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials von Morice, P.-M., Ray-Coquard, I., Moore, K.N., Diéras, V., Alexandre, J.

Volltext

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors von Italiano, A., Infante, J.R., Shapiro, G.I., Moore, K.N., LoRusso, P.M., Hamilton, E., Cousin, S., Toulmonde, M., Postel-Vinay, S., Tolaney, S., Blackwood, E.M., Mahrus, S., Peale, F.V., Lu, X., Moein, A., Epler, J., DuPree, K., Tagen, M., Murray, E.R., Schutzman, J.L., Lauchle, J.O., Hollebecque, A., Soria, J.-C.

Volltext

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube... von Duska, L.R., Petroni, G.R., Varhegyi, N., Brown, J., Jelovac, D., Moore, K.N., McGuire, W.P., Darus, C., Barroilhet, L.M., Secord, A.A.

Volltext

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary da... von Wade, K.N. Slaughter, Brady, M.F., Thai, T., Wang, Y., Zheng, B., Salani, R., Tewari, K.S., Gray, H.J., Bakkum-Gamez, J.N., Burger, R.A., Moore, K.N., Bookman, M.A.

Volltext

A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tu... von Duska, L.R., Krasner, C.N., O'Malley, D.M., Hays, J.L., Modesitt, S.C., Mathews, C.A., Moore, K.N., Thaker, P.H., Miller, A., Purdy, C., Zamboni, W.C., Lucas, A.T., Supko, J.G., Schilder, R.J.

Volltext

Long-term bladder management by intermittent catheterisation in adults and children von Moore, K N, Fader, M, Getliffe, K

Volltext

PARPi after PARPi in epithelial ovarian cancer von Essel, K.G., Behbakht, K., Lai, T., Hand, L., Evans, E., Dvorak, J., Ding, K., Konecny, G., Moore, K.N.

Volltext

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of... von Matulonis, U.A., Moore, K.N., Martin, L.P., Vergote, I.B., Castro, C., Gilbert, L., Malek, K., Birrer, M.J., O’Malley, D.M.

Volltext